Clinical Trials Browser

Small Cell Lung Carcinoma × durvalumab × 1 year × Clear all

NCT07391670 2026-04-17

IMFINZI-subQ

Phase 1 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT07005128 2026-04-16

DeLLphi-312

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07531095 2026-04-15

DeLLphi-313

Phase 1 Not yet recruiting

Small Cell Lung Carcinoma

NCT06780137 2026-04-13

MK-6070-002

Phase 1/2 Recruiting

Small Cell Lung Carcinoma

NCT07339059 2026-04-09

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05903092 2026-04-07

MOZART

Phase 2 Suspended

Small Cell Lung Carcinoma

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Phase 1 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06769126 2026-03-30

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06992609 2026-03-25

ALBORAN

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07459634 2026-03-10

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05683977 2026-02-24

ARSENAL

Active not recruiting

Small Cell Lung Carcinoma

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07149363 2026-02-17

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06898957 2026-02-05

(DeLLphi-310)

Phase 1 Recruiting

Small Cell Lung Carcinoma

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Phase 1/2 Recruiting

EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06211036 2025-12-17

DeLLphi-305

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT04745689 2025-12-10

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT04397003 2025-10-22

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 3 FDA

Small Cell Lung Carcinoma

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Phase 2 Active not recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05796089 2025-08-26

CHEST RT

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

NCT06826677 2025-06-24

ARAL

Small Cell Lung Carcinoma

NCT05617963 2025-06-15

DURVALUNG

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Small Cell Lung Carcinoma

NCT06419179 2025-05-20

GUIDANCE

Phase 2 Enrolling by invitation

Small Cell Lung Carcinoma